TheraSphere With and Without Durvalumab and Tremelimumab for HCC
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The objective of the ROWAN clinical study is to assess the the durability of local tumor
control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab,
compared to those who receive TheraSphere treatment alone.